论文部分内容阅读
目的:探讨磁导向甲氨蝶呤缓释药物(FM-MTX)的形貌特征及缓释特性。方法:采用分光光谱法、扫描电镜、透射电镜、X射线能谱分析等手段检测磁导向甲氨蝶呤缓释药物的含量及组成,并对FM-MTX的形貌特征及缓释特性进行检测。结果:化学交联法制备出磁导向甲氨蝶呤白蛋白缓释药物,其药物含量稳定。颗粒直径约(0.8±0.14)μm。在梯度磁场下比磁矩σs为0.9A·m2/kg。在0.9%氯化钠及RPMI1640培养液6h仅有30.5%药物释放到介质中,24h释药量约60%,48h接近78%。结论:以化学交联法制得的磁导向甲氨蝶呤缓释药物FM-MTX含量稳定,在体外具有缓释作用
Objective: To investigate the morphological characteristics and sustained-release properties of magnetic-guided methotrexate sustained-release drug (FM-MTX). Methods: The content and composition of magnetic methotrexate sustained-release drug were detected by spectrophotometry, scanning electron microscopy, transmission electron microscopy and energy dispersive X-ray spectroscopy. The morphological characteristics and sustained-release properties of FM-MTX were detected . Results: The magnetic crosslinked methotrexate albumin sustained-release drug was prepared by chemical cross-linking method, and its drug content was stable. The particle diameter is about (0.8 ± 0.14) μm. In the gradient magnetic field than the magnetic moment σs 0.9A · m2 / kg. In 0.9% sodium chloride and RPMI1640 medium 6h only 30.5% of the drug released into the medium, 24h release of about 60%, 48h close to 78%. Conclusion: The methotrexate sustained release drug FM-MTX prepared by chemical cross-linking method has stable content and sustained release in vitro